The Comprehensive Study of Clinical Effect and Safety for the Patients with Knee Osteoarthritis Treated by Sodium Hyaluronate and Xianlinggubao Alone and in Combination
Author:
Affiliation:
Department of Pharmacy, Xuancheng People’s Hospital, Xuancheng 242000, China
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
摘要:
目的 观察独用与合用仙灵骨葆和玻璃酸钠治疗膝骨关节炎的临床效果比较。方法 自2015年10月至2016年10月在我院治疗的膝骨关节炎患者90例,按照随机分配原则平均分为A、B、C 3组30例。其中,A组单独采用仙灵骨葆进行治疗;B组单独采用玻璃酸钠进行治疗;C组仙灵骨葆与玻璃酸钠合用进行治疗。观察各组WOMAC(Western Ontario and McMaster Universities)量表得分与治疗不良反应状况。结果 C组患者的WOMAC得分为17,31±6.90,明显低于A组与B组的30.43±7.07和28.25±7.19,且3组比较,P<0.05,差异具有统计学意义,无不良反应。结论 单用仙灵骨葆或玻璃酸钠均可治疗膝骨关节炎,如将两者合用,可以取得更好疗效,值得临床推广。
Abstract:
Objective To research the effect and safety of sodium hyaluronate and xianlinggubao alone and in combination for the patients with knee osteoarthritis. Methods During the time of October 2014 to October 2016, 90 patients with knee osteoarthritis were selected and divided into A, B and C groups with the principle of voluntary and randomly assignment. The 30 patients ingroup A were treated by xianlinggubao only and the 30 patients ingroup B were treated by sodium hyaluronate only, while the 30 patients in group C were treated by sodium hyaluronate and xianlinggubao. To observe the WOMAC scores and adverse events of the 3 groups. Results The WOMAC score in group C was 17.31±6.90, significantly lower than the that of group A and group B, which were 30.43±7.07 and 28.25±7.19, and the results above were statistically significance while P<0.05. From the view of adverse reactions, there were no patients appeared adverse reaction in group C. Conclusion Sodium hyaluronate and xianlinggubao alone and in combination all can treated knee osteoarthritis, but compared with using xianlinggubao and sodium hyaluronate alone. It can effectively improve the clinical efficacy to use them in combination which can also cut down the adverse reactions and deserved to be used in clinical.